Véronique Diéras, MD, of Institut Curie Paris & Saint Cloud, discusses results from the phase III BROCADE 3 trial, which investigated the PARP inhibitor veliparib in combination with carboplatin/paclitaxel in patients with advanced HER2-negative, germline BRCA–mutated breast cancer (Abstract LBA9).
Mansoor R. Mirza, MD, of Copenhagen University Hospital, offers his perspective on three studies presented in the Presidential Symposium: the PRIMA/ENGOT-OV26/ GOG-3012 trial (niraparib for newly diagnosed advanced disease); the PAOLA-1/ENGOT-ov25 trial (olaparib plus bevacizumab maintenance therapy in newly diagnosed advanced disease); and the VELIA/COG-3005 study (integrating veliparib with front-line chemotherapy and maintenance therapy) (Abstracts LBA 1–4).
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses the efficacy of prostate radiotherapy plus androgen-deprivation therapy with or without docetaxel in patients with prostate cancer with only lymph node metastases or less than four bone metastases (Abstract 844O).
Thomas Powles, MD, PhD, of Queen Mary University of London, and Enrique Grande, MD, PhD, of MD Anderson Cancer Center, Madrid, discuss findings of the phase III IMvigor130 trial on the efficacy and safety of atezolizumab as monotherapy or combined with platinum-based chemotherapy vs placebo plus platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (Abstract LBA14).
Volker Kunzmann, MD, of the University of Würzburg/Comprehensive Cancer Center Mainfranken, discusses the final results of a phase II multicenter trial on the conversion rate in locally advanced pancreatic cancer after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (Abstract 671O).
Robin L. Jones, MD, MBBS, of The Royal Marsden/Institute of Cancer Research, discusses the first phase III study in angiosarcoma, which showed no difference in outcome between pazopanib vs pazopanib plus the novel monoclonal antibody TRC105 (Abstract 1667O).
